Pyxis Oncology (NASDAQ:PYXS) Stock Rating Reaffirmed by Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report released on Thursday morning, Benzinga reports. The firm currently has a $7.00 price objective on the stock.

A number of other research firms have also recently commented on PYXS. HC Wainwright reiterated a buy rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Friday, August 16th. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a report on Thursday, August 8th. They set a buy rating and a $10.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Pyxis Oncology has an average rating of Buy and an average target price of $9.00.

Pyxis Oncology Stock Up 0.3 %

NASDAQ:PYXS opened at $3.69 on Thursday. The company’s 50 day moving average price is $3.59 and its 200-day moving average price is $3.97. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The stock has a market cap of $217.30 million, a price-to-earnings ratio of -2.71 and a beta of 1.28.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. As a group, sell-side analysts anticipate that Pyxis Oncology will post -1.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Decheng Capital LLC bought a new position in Pyxis Oncology in the fourth quarter worth approximately $588,000. Vestal Point Capital LP purchased a new position in shares of Pyxis Oncology during the 4th quarter worth $792,000. Cable Car Capital LLC purchased a new position in shares of Pyxis Oncology during the 4th quarter worth $111,000. SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology during the 1st quarter worth $59,000. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Pyxis Oncology during the 1st quarter worth $351,000. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.